Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Authors:

Abstract
No abstract available
Funding Information
  • Coalition for Epidemic Preparedness Innovations
  • Horizon 2020 Framework Programme
  • Deutsche Forschungsgemeinschaft (398066876/GRK 2485/2)

This publication has 29 references indexed in Scilit: